Skip to main content
Have a personal or library account? Click to login
Emergency anticancer therapy in intensive care medicine: A mainland China survey Cover

Emergency anticancer therapy in intensive care medicine: A mainland China survey

Open Access
|Jul 2026

Abstract

Objective

To identify intensivists‘ attitudes toward emergency anticancer therapy (EAT) in patients with cancer in intensive care units (ICUs).

Material and methods

A 11-question survey was performed among intensivists in the Cancer Critical Care Medicine Committee of the Chinese Anti-Cancer Association and Critical Care Medicine Committee of Beijing Association of Oncology between November 11 and December 11, 2024. Response were compared between mixed and oncologic ICU physicians.

Results

In total, 120 intensivists completed the survey. For 9 of 11 questions, the agreement rate exceeded 85%. There were 61.5% mixed ICU physicican and 35.5% oncologic ICU physicians in favor of compostion of the composition of a multidisciplinary team (MDT) composing of an intensivist, an oncologis and a pharmacist, respectively. However this difference was not significant (P=0.281).

Conclusions

Intensivists in China generally hold positive attitudes toward emergency anticancer therapy in ICUs for critically ill patients with cancer-related organ dysfunction. However, opinions differ regarding the MDT composition between mixed and oncologic ICU physicicans.

DOI: https://doi.org/10.62838/jccm-2026-0019 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 438 - 443
Submitted on: Jun 27, 2025
Accepted on: Jan 21, 2026
Published on: Jul 27, 2026
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Hao Zhang, DongHao Wang, ChangSong Wang, Xue-Zhong Xing, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.